297 related articles for article (PubMed ID: 21258214)
1. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Beljanski V; Lewis CS; Smith CD
Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
[TBL] [Abstract][Full Text] [Related]
2. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.
Beljanski V; Knaak C; Zhuang Y; Smith CD
Invest New Drugs; 2011 Dec; 29(6):1132-42. PubMed ID: 20473784
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
5. A novel sphingosine kinase inhibitor induces autophagy in tumor cells.
Beljanski V; Knaak C; Smith CD
J Pharmacol Exp Ther; 2010 May; 333(2):454-64. PubMed ID: 20179157
[TBL] [Abstract][Full Text] [Related]
6. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
7. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
8. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
White MD; Chan L; Antoon JW; Beckman BS
Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
[TBL] [Abstract][Full Text] [Related]
9. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
Zhou J; Chen J; Yu H
Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis.
Snider AJ; Ruiz P; Obeid LM; Oates JC
PLoS One; 2013; 8(1):e53521. PubMed ID: 23301082
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.
Britten CD; Garrett-Mayer E; Chin SH; Shirai K; Ogretmen B; Bentz TA; Brisendine A; Anderton K; Cusack SL; Maines LW; Zhuang Y; Smith CD; Thomas MB
Clin Cancer Res; 2017 Aug; 23(16):4642-4650. PubMed ID: 28420720
[No Abstract] [Full Text] [Related]
17. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
[TBL] [Abstract][Full Text] [Related]
18. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
19. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells.
McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S
Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645
[TBL] [Abstract][Full Text] [Related]
20. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]